Lianyong Chen

Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 19 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1000 Talent Plan, and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin - a multi-billion drug. Mr. Chen was a Post-Doc at MIT, Ph.D. (with top honor) from the University of Louvain, Louvain-La-Neuve, B.S. from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.